Neutral endopeptidase and angiotensin-converting enzyme inhibitors increase nitric oxide production in isolated canine coronary microvessels by a kinin-dependent mechanism

Journal of Cardiovascular Pharmacology

Volumn 31, Issue 4, 1998, Pages 623-629

  Zhang, Xiaoping ^a   Nasjletti, Alberto ^a   Xu, Xiaobin ^a   Hintze, Thomas H ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Phosphoamridon; Ramaprilat; Serine proteases; Thiorphan

Indexed keywords

BRADYKININ B2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENZYME INHIBITOR; ICATIBANT; ISOCOUMARIN DERIVATIVE; MEMBRANE METALLOENDOPEPTIDASE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; PHOSPHORAMIDON; RAMIPRILAT; SERINE PROTEINASE INHIBITOR; THIORPHAN;

ANIMAL TISSUE; ARTICLE; CORONARY ARTERY BLOOD FLOW; DOG; DRUG EFFECT; ENZYME INHIBITION; KALLIKREIN KININ SYSTEM; NONHUMAN; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM; VASODILATATION;

EID: 0031954807     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199804000-00023     Document Type: Article

References (41)

1. Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 1992;44:1-80.
2. Linz W, Wiemer G, Scholkens BA. Role of kinins in the pathophysiology of myocardial ischemia. Diabetes 1996;45(suppl 1): S51-8.
3. Graf H, Grafe M, Bossaller C, et al. Degradation of bradykinin by neutral endopeptidase (EC 3.4.23.11) in cultured human endothelial cells. Eur J Clin Chem Clin Biochem 1993;31:267-72.
4. Dragovic T, Minshall R, Jackman HL, Wang LX, Erdos KG. Kininase II-type enzymes. Diabetes 1996;45(suppl 1):S34-7.
5. Carretero OA, Scicli AG. Zinc metallopeptidase inhibitors: a novel antihypertensive treatment. Hypertension 1991;68:366-71.
6. Fink CA, Qiao Y, Berry CJ, Sakane Y, Ghai RD, Trapani AJ. New α-thiol dipeptide dual inhibitors of angiotensin-I converting enzyme and neutral endopeptidase EC 3.4.24.11. J Med Chem 1995; 38:5023-30.
7. Trippodo NC, Robl JA, Asaad MM, et al. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure. J Pharmacol Exp Ther 1995;275:745-52.
8. Skidgel RA. Bradykinin-degrading enzymes: structure, function, distribution, and potential roles in cardiovascular pharmacology. J Cardiovasc Pharmacol 1992;20(suppl 9):S4-9.
9. Erdos KG, Skidgel RA. Neutral endopeptidase 2.4.11 (enkephalinase) and related regulators of peptide hormones. FASEB J 1989; 3:145-51.
10. Fournie-Zaluski MC, Coric P, Turcaud S, et al. New dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme: rational design, bioavailability, and pharmacological response in experimental hypertension. J Med Chem 1994;37:1070-83.
11. Llorens-Cortest C, Huang H, Vicart P, Gasc JM, Paulin D, Corvol P. Identification and characterization of neutral endopeptidase in endothelial cells from venous or arterial origins. J Biol Chem 1992;267:14012-8.
12. Mombouli JV, Vanhoutte PM. Kinins mediate kallikrein-induced endothelium-dependent relaxations in isolated canine coronary arteries. Biol Biophy Res Commun 1992;185:693-7.
13. Linz W, Wiemer G, Scholkens BA. Contribution of bradykinin to the cardiovascular effects of ramipril. J Cardiovasc Pharmacol 1993;22(suppl 9):S1-8.
14. Vanhoutte PM, Boulanger CM, Illiano SC, Vidai M, Mombouli JV. Endothelium-dependent effects of converting-enzyme inhibitors. J Cardiovasc Pharmacol 1993;22(suppl 5):S10-6.
15. Wiemer G, Popp R, Scholkens BA, Gogelein L. Enhancement of cytosolic calcium, prostacyclin and nitric oxide by bradykinin and the ACE inhibitor ramiprilat in porcine brain capillary endothelial cells. Brain Res 1994;638:261-6.
16. Zhang X, Xie Y-W, Nasjletti A, Xiaobin X, Wolin MS, Hintze TH. ACE inhibitors promote nitric oxide accumulation to modulate myocardial oxygen consumption. Circulation 1997;95:176-82.
17. Kichuk MR, Seyedi N, Zhang XP, et al. Regulation of nitric oxide production in human coronary microvessels and the contribution of local kinin formation. Circulation 1996;94:44-51.
18. Gerritsen ME, Printz MP. Sites of prostaglandin synthesis in the bovine heart and isolated bovine coronary microvessels. Circ Res 1981;49:1152-63.
19. Roques BP, Noble F, Dauge V, Fournie-Zaluski MC, Beaumont. Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev 1993;45:87-146.
20. Grafford JT, Skidgel RA, Erdos EG, Hersh LB. Human kidney "enkephalinase," a neutral endopeptidase that cleaves active peptides. Biochemistry 1983;22:3265-71.
21. Soleilhac JM, Sucas E, Turcuad VS, et al. A 94-kDa protein, identified as neutral endopeptidase-24.11, can inactivate atrial natriuretic peptide in the vascular endothelium. Mol Pharmacol 1992; 41:609-14.
22. Erdos KG. Some old and some new ideas on kinin metabolism. J Cardiovasc Pharmacol 1990;15(suppl 6):S20-4.
23. Pham I, Gonzalez W, Amrani Aike, et al. Effect of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension. J Pharmacol Exp Ther 1993;265:1339-47.
24. Ura N, Carretero OA, Erdos EG. Role of renal endopeptidase 24.11 in kinin metabolism in vitro and in vivo. Kidney Int 1987;32:507-13.
25. Shimamoto K, Ura N, Iimura O. The natriuretic mechanisms of neutral endopeptidase inhibitor in rats. Braz J Med Biol Res 1994;27:1956-73.
26. Seymour AA, Sheldon JH, Smith PL, Asaad M, Rogers WL. Potential of the renal responses to bradykinin by inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in anesthetized dogs. J Pharmacol Exp Ther 1989;250:624-31.
27. Ura N, Shimamoto K, Kuroda S, et al. The role of kinins and atrial natriuretic peptide on the renal effects of neutral endopeptidase inhibitor in rats. Clin Exp Hypertens 1994;16(6):799-808.
28. Ura N, Shimamoto K, Nomura N, et al. The mechanisms of the renal effects of neutral endopeptidase inhibitor in rats. Clin Exp Hypertens 1995;17(8):1183-96.
29. Nomura N, Shimamoto K, Ura N, et al. The role of kinins and atrial natriuretic peptide on the renal effects of neutral endopeptidase inhibitor in normotensive and hypertensive rats. Clin Exp Hypertens 1995;17(8):1219-31.
30. Johnson AR, Ashton J, Schulz WW, Erdos EG. Neutral metalloendopeptidase in human lung tissue and cultured cells. Am Rev Respir Dis 1985;132:564-8.
31. Tamburini P, Koehn JA, Gilligan JP, et al. Rat vascular tissue contains a neutral endopeptidase capable of degrading atrial natriuretic peptide. J Pharmacol Exp Ther 1989;251:956-61.
32. Piedimonte G, Nadel JA, Long CS, Hoffman JIE. Neutral endopeptidase in the heart: neutral endopeptidase inhibition prevents isoproterenol-induced myocardial hypoperfusion in rats by regulating bradykinin degradation: some old and some new ideas on kinin metabolism. Circ Res 1994;75:770-9.
33. Graf K, Koehne P, Grafe M, Zhang M, Auch-Schwelk W, Fleck E. Regulation and differential expression of neutral endopeptidase 24.11 in human endothelial cells. Hypertension 1995;26:230-5.
34. Graf K, Grafe M, Auch-Schwelk W, et al. Tissue kallikrein activity and release in human endothelial cells. Eur J Clin Chem Clin Biochem 1994;32:495-500.
35. Seymour AA, Asaad M, Lanoce VM, Langenbacher KM, Fennel SA, Rogers WL. Systemic hemodynamics, renal function and hormonal levels during inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in conscious dogs with pacing-induced heart failure. J Pharmacol Exp Ther 1993;266:872-83.
36. Marie C, Mossiat C, Lecomte JM, Schwartz JC, Bralet J. Hemodynamic effects of acute and chronic treatment with aladotril, a mixed inhibitor of neutral endopeptidase and angiotensin I-converting enzyme, in conscious rats with myocardial infarction. J Pharmacol Exp Ther 1995;275:1324-31.
37. Trippodo NC, Panchal BC, Fox M. Repression of angiotensin II and potentiation of bradykinin contribute to the synergistic effects of dual metalloprotease inhibition in heart failure. J Pharmacol Exp Ther 1995;272:619-27.
38. Trippodo NC, Fox M, Natarajan V, Panchal BC, Dorso CR, Asaad MM. Combined inhibition of neutral endopeptidase and angiotensin converting enzyme in cardiomyopathic hamsters with compensated heart failure. J Pharmacol Exp Ther 1993;267:108-16.
39. Auch-Schwelf W, Bossaller C, Claus M, et al. ACE inhibitors are endothelium dependent vasodilator of coronary arteries during submaximal stimulation with bradykinin. Cardiovasc Res 1993; 27:312-7.
40. Hecker M, Porsti I, Busse R. Mechanisms involved in the angiotensin II-independent hypotensive active of ACE inhibitors. Brazil J Med Biol Res 1994;27:1917-21.
41. Seyedi N, Xu X, Nasjletti A, Hintze TH. Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension 1995;26:164-70.